Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 386,035 shares, a drop of 23.1% from the January 29th total of 502,013 shares. Approximately 11.2% of the company’s shares are short sold. Based on an average daily volume of 357,684 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily volume of 357,684 shares, the days-to-cover ratio is currently 1.1 days. Approximately 11.2% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JAGX. Wall Street Zen cut Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $60.00.

Jaguar Animal Health Trading Up 9.0%

JAGX opened at $0.97 on Monday. The company’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $1.44. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52. The firm has a market capitalization of $3.62 million, a price-to-earnings ratio of -0.03 and a beta of 0.09. Jaguar Animal Health has a fifty-two week low of $0.56 and a fifty-two week high of $15.75.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.